 Clinical immunologic responses Haemophilus type b-tetanus toxoid conjugate vaccine infants months age safety immunogenicity Haemophilus influenzae type b-tetanus toxoid conjugate vaccine Hib-TT healthy infants injections months age serious local systemic reactions first injection geometric mean Hib antibody level micrograms/ml subsequent injection significant rise geometric mean percentage vaccinees Hib antibody levels micrograms/ml serum first second third Hib-TT injection percentage months age fourth injection Control infants diphtheria-tetanus toxoid-pertussis vaccine nondetectable levels second injection Hib-TT increases Hib antibody isotypes IgG IgM IgA IgG increases All subjects U/ml TT antibody protective level study Hib-TT months safe induces protective levels antibodies age incidence meningitis Hib